BIOLIGHT(300246)

Search documents
宝莱特:2024年半年度非经营性资金占用及其他关联资金往来情况汇总表
2024-08-28 10:45
2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位:广东宝莱特医用科技股份有限公司 单位:万元 | | 天津宝莱特医用科 | 全资子公司 | 其他会计科目 | 4,801.96 | | 23.74 | 4,825.70 | - | 借款 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 技有限公司 | | | | | | | | | | | | 天津市博奥天盛塑 | 全资子公司 | 其他会计科目 | 50.00 | 150.00 | 0.56 | | 200.56 | 借款 | 非经营性往来 | | | 材有限公司 | | | | | | | | | | | | 天津市挚信鸿达医 疗器械开发有限公 | 全资子公司 | 其他会计科目 | 514.30 | | 7.98 | 300.00 | 222.28 | 借款 | 非经营性往来 | | | 司 | | | | | | | | | | | | 珠海市宝瑞医疗器 | 控股子公司 | 其他会计科目 | | | | | | 借款 ...
宝莱特:监事会决议公告
2024-08-28 10:45
证券代码:300246 证券简称:宝莱特 公告编号:2024-068 债券代码:123065 债券简称:宝莱转债 广东宝莱特医用科技股份有限公司 第八届监事会第十五次会议决议公告 经审核,监事会认为董事会编制和审核的公司《2024年半年度报告》及摘要 程序符合法律、行政法规和中国证监会的相关规定,报告内容真实、准确、完整 地反映了公司的实际情况,不存在任何虚假记载,误导性陈述或者重大遗漏。具 体内容详见公司于信息披露网站巨潮资讯网(http://www.cninfo.com.cn)披露的 《2024年半年度报告》及摘要。 (以上议案同意 3 票,弃权 0 票,反对 0 票) 二、 审议通过了《2024 年半年度募集资金存放与使用情况专项报告》 经审核,监事会认为:2024年上半年公司募集资金的存放和使用情况符合中 国证监会、深圳证券交易所关于上市公司募集资金存放和使用的相关规定,不存 在募集资金存放和使用违规的情形。具体内容详见公司于信息披露网站巨潮资讯 网(http://www.cninfo.com.cn)披露的相关公告。 (以上议案同意3票,弃权0票,反对0票) 债券代码:123065 债券简称:宝莱转债 ...
宝莱特:2024年半年度募集资金存放与使用情况专项报告
2024-08-28 10:45
广东宝莱特医用科技股份有限公司 2024 年半年度募集资金存放与使用情况专项报告 广东宝莱特医用科技股份有限公司 2024 年半年度募集资金存放与使用情况的专项报告 一、 募集资金基本情况 (一)公开发行可转换公司债券 经中国证券监督管理委员会证监许可[2020]1831 号文核准,并经深圳证券交易所同意, 本公司由主承销商开源证券股份有限公司于 2020 年 9 月 4 日向不特定对象发行可转换公司 债券 219 万张,每张面值 100 元,发行价格为每张人民币 100 元。截止 2020 年 9 月 10 日, 本公司共募集资金人民币 219,000,000.00 元(大写人民币贰亿壹仟玖佰万元整),扣除与 发行有关的费用(不含税)人民币 6,322,547.18 元后,实际募集资金净额为人民币 212,677,452.82 元(大写人民币贰亿壹仟贰佰陆拾柒万柒仟肆佰伍拾贰元捌角贰分)。 截止 2020 年 9 月 10 日,本公司上述发行募集的资金已全部到位,业经大华会计师事务 所(特殊普通合伙)以"大华验字[2020]000539 号"验资报告验证确认。 截止 2024 年 6 月 30 日,募集资金 ...
宝莱特(300246) - 2024 Q2 - 季度财报
2024-08-28 10:43
Financial Performance - Revenue for the reporting period was RMB 536.47 million, a decrease of 19.35% compared to the same period last year[11] - Net profit attributable to shareholders of the listed company was RMB -2.51 million, a decrease of 104.27% year-on-year[11] - Net cash flow from operating activities was RMB -38.37 million, a decrease of 831.80% compared to the same period last year[11] - Basic earnings per share were RMB -0.0095, a decrease of 103.07% year-on-year[11] - Total assets at the end of the reporting period were RMB 2.59 billion, an increase of 2.21% compared to the end of the previous year[11] - Net assets attributable to shareholders of the listed company were RMB 1.29 billion, a decrease of 1.75% compared to the end of the previous year[11] - Revenue decreased by 19.35% to RMB 536.47 million compared to the same period last year[62] - Net profit dropped by 101.53% to a loss of RMB 930,489.92 due to reduced revenue[62] - Operating cash flow decreased by 831.80% to a negative RMB 38.37 million, primarily due to reduced cash received from sales[62] - R&D investment decreased by 11.08% to RMB 41.50 million[62] - Long-term loans increased by 122.07% to RMB 196.17 million due to increased bank borrowing by subsidiaries[62] - Fixed assets increased by 41.44% to RMB 698.37 million as some construction-in-progress projects reached usable status[62] - Net profit attributable to parent company owners decreased by 104.27% to -2,514,995.82 RMB, primarily due to a decline in operating revenue[63] - Comprehensive income decreased by 102.23% to -1,416,348.95 RMB, mainly due to reduced operating revenue[63] - Earnings per share dropped by 103.07% to -0.0095 RMB, driven by a decrease in net profit[63] - Revenue from monitoring products decreased by 45.54% to 133,301,061.27 RMB, with a gross margin decline of 2.45%[64] - Revenue from dialysis products decreased by 1.42% to 398,563,997.18 RMB, with a gross margin decline of 4.52%[64] - Investment income was 4,259,292.52 RMB, accounting for -211.35% of total profit, mainly from large deposit interest income[65] - Fixed assets increased by 7.48% to 698,369,424.39 RMB, as some construction projects reached usable status[65] - Long-term loans increased by 4.08% to 196,174,000.00 RMB, due to increased bank borrowing by subsidiaries[65] - Inventory decreased by 0.50% to 212,465,113.07 RMB, reflecting reduced stock levels[65] - Other comprehensive income decreased by 0.02% to -908,781.63 RMB, due to foreign currency translation differences in overseas subsidiaries[66] - Restricted assets at the end of the reporting period amounted to RMB 21,455,818.16, a decrease from RMB 38,770,299.17 at the beginning of the period, primarily due to guarantees and frozen deposits[68] - Total investment during the reporting period reached RMB 49,907,003.00, a significant increase of 271.18% compared to RMB 13,445,400.00 in the same period last year[69] - The company's financial assets measured at fair value remained stable at RMB 2,000,000.00, with no significant changes in fair value during the reporting period[70] - Total raised funds amounted to RMB 75,900,000.00, with RMB 2,658,100.00 invested during the reporting period and a cumulative investment of RMB 48,765,370.00[71] - The company issued convertible bonds totaling RMB 219,000,000.00 in 2020, with a net raised amount of RMB 212,677,452.82 after deducting issuance costs[71] - As of June 30, 2024, the company had fully utilized the RMB 21,853,990.00 raised from convertible bonds, leaving a balance of RMB 0 in the fundraising account[71] - In 2021, the company raised RMB 539,999,995.20 through a private placement of 28,723,404 shares at RMB 18.80 per share, with a net raised amount of RMB 528,049,313.53 after deducting issuance costs[73] - The Blood Purification Industry Base and R&D Center project has achieved 100% of its investment target, with RMB 15,951,750.00 invested as of the reporting period[74] - The Marketing Network and Informatization Construction project has reached 41.52% of its investment target, with RMB 1,453,050.00 invested as of the reporting period[74] - The company's supplementary working capital projects have been fully utilized, with a total investment of RMB 19,807,610.00 across both convertible bonds and private placement funds[74] - The total investment for the "Baolai Blood Purification Industrial Base and R&D Center Project" has been adjusted to RMB 572.7752 million, with an increase of RMB 133.875 million[76] - The investment for the "Blood Purification Industrial Base Project" has been adjusted to RMB 518.7752 million, with an increase of RMB 127.875 million[76] - The investment for the "Blood Purification R&D Center Project" has been adjusted to RMB 54 million, with an increase of RMB 6 million[76] - The company plans to transfer 12 million units of dialyzer production capacity to Suzhou Junkan Medical Technology Co., Ltd., with the remaining 8 million units to be placed at the Baolai Blood Purification Industrial Base[76] - The total planned investment for the dialyzer production line is RMB 70 million, with RMB 70 million to be invested from raised funds[76] - The company has used RMB 15.0002 million of raised funds to replace pre-invested self-raised funds in the raised funds investment projects[76] - As of June 30, 2024, the balance of raised funds is RMB 269,774,377.59, with RMB 196,119,408.35 of temporarily idle raised funds used for cash management[76] - The total investment for the "Baolai Blood Purification Industrial Base and R&D Center Project" has been adjusted to 572.7752 million yuan, an increase of 133.875 million yuan, with 518.7752 million yuan allocated to the industrial base and 54 million yuan to the R&D center[77] - The company plans to transfer 12 million units of dialyzer production capacity to its subsidiary Suzhou Junkan Medical Technology Co., Ltd., while retaining 8 million units at the Baolai Blood Purification Industrial Base[79] - The "Baolai Blood Purification Industrial Base and R&D Center Project" has a total planned investment of 70 million yuan, all of which will be used to purchase dialyzer production lines and auxiliary equipment[79] - The company has used 25 million yuan of raised funds to increase capital in its wholly-owned subsidiary Shenzhen Baoyuan Medical Equipment Co., Ltd. for the "Marketing Exhibition Center and Logistics Distribution Construction Project"[77] - The company has provided a maximum loan of 70 million yuan to its subsidiary Suzhou Junkan Medical Technology Co., Ltd. using part of the raised funds for the implementation of the fundraising project[77] - The "Baolai Blood Purification Industrial Base and R&D Center Project" has achieved a cumulative investment of 115.5295 million yuan, with an investment progress of 32.54%[78] - The "Marketing Network and Informatization Construction Project" has achieved a cumulative investment of 14.5305 million yuan, with an investment progress of 41.52%[78] - Both the "Baolai Blood Purification Industrial Base and R&D Center Project" and the "Marketing Network and Informatization Construction Project" have been extended to June 30, 2025[79] - The company has adjusted the internal investment structure of the "Marketing Network and Informatization Construction Project" and changed the implementation method of the dialyzer production line in the "Baolai Blood Purification Industrial Base and R&D Center Project"[79] - Revenue from blood dialysis consumables production and sales for Tianjin Zhixin Hongda Medical Device Development Co., Ltd. was RMB 22,805,379.46, with a net loss of RMB 513,708.02[85] - Tianjin Boao Tiansheng Plastic Materials Co., Ltd. reported revenue of RMB 198,362.05 and a net loss of RMB 2,242,466.00[85] - Liaoning Hengxin Biotechnology Co., Ltd. achieved revenue of RMB 45,506,938.75 and a net profit of RMB 1,731,518.89[85] - Sichuan Baolai Tezhili Medical Technology Co., Ltd. recorded revenue of RMB 2,490,055.28 and a net loss of RMB 2,345,807.43[85] - Changzhou Huayue Minimally Invasive Medical Devices Co., Ltd. generated revenue of RMB 53,308,995.99 and a net profit of RMB 3,711,753.47[85] - Wuhan Keruidi Medical Products Co., Ltd. reported revenue of RMB 47,267,950.04 and a net profit of RMB 1,168,596.07[85] - Wuhan Qicheng Biotechnology Co., Ltd. achieved revenue of RMB 37,911,936.52 and a net profit of RMB 3,144,509.94[85] - Nanchang Baolai Te Medical Devices Co., Ltd. recorded revenue of RMB 8,261,599.53 and a net loss of RMB 716,094.16[85] - Zhuhai Baorui Medical Devices Co., Ltd. generated revenue of RMB 27,750,402.84 and a net profit of RMB 869,071.21[85] - Shenzhen Baoyuan Medical Devices Co., Ltd. reported revenue of RMB 122,407,810.21 and a net profit of RMB 4,757,812.61[85] - The company holds a 60% stake in Changzhou Huayue Minimally Invasive Medical Devices Co., Ltd., which specializes in the R&D, production, and sales of hemodialysis powder and hemodialysis concentrate, primarily covering the East China market[87] - Wuhan Keruidi Medical Supplies Co., Ltd., in which the company holds a 62.08% stake, focuses on the R&D, production, sales of hemodialysis powder and concentrate, with sales mainly in Central China[87] - Wuhan Qicheng Biotechnology Co., Ltd., with a 55% stake held by the company, is a professional manufacturer of medical water treatment equipment, including dialysis water treatment systems and disinfection systems[87] - Nanchang Baolai Medical Devices Co., Ltd., a wholly-owned subsidiary, is engaged in the R&D, production, and sales of hemodialysis powder and concentrate, primarily serving the South China market[88][89] - Zhuhai Baorui Medical Devices Co., Ltd., with an 85% stake held by the company, acts as a distributor for hemodialysis products, focusing on market expansion in the Southwest region[89] - Shenzhen Baoyuan Medical Devices Co., Ltd., a wholly-owned subsidiary, is a distributor for hemodialysis products, targeting market expansion in South China, particularly Guangdong[89] - Suzhou Junkan Medical Technology Co., Ltd., with a 92.12% stake held by the company, has a registered capital of 291.8741 million RMB and is involved in medical technology development[90] - The company has fully mastered the production of hemodialysis membranes and hemodialyzers, achieving a complete layout in the blood purification industry chain[91] - The demand for hemodialysis products is expected to continue rising due to the increasing aging population and the growing number of uremia patients in China[92] - The company has obtained the "Medical Device Registration Certificate" for its automated peritoneal dialysis machine and disposable peritoneal dialysis tubing[92] - The centralized procurement policy for high-value medical consumables may lead to price and profit margin declines, but the company sees a positive impact on dialysis filters due to economies of scale[93] - The company has proactively adapted to the "two-invoice system" policy by building platform-based distributors to integrate and expand the market in the blood dialysis field[93] - The company is constructing a self-sustaining ecosystem in the blood purification field, covering product manufacturing, channel construction, medical services, and information management[94] - The company faces management risks due to business expansion and increased business models, and is implementing group management to optimize governance and enhance operational efficiency[94] - Rising raw material costs pose a risk to the company's profitability, despite efforts to control costs through supply chain integration[94] - Overseas market sales are exposed to risks from exchange rate policies, economic policies, trade policies, and government stability, which could impact the company's profitability[94] - The company has a significant demand for high-quality technical and management talents, but faces challenges in talent retention and attraction due to intense industry competition[95] - The company has implemented a competitive employee compensation scheme and internal incentives linking R&D achievements to promotions and salaries[95] - In 2022, the company granted 865,830 restricted shares to 111 incentive recipients at an adjusted price of 13.68 yuan per share[99] - In 2022, the company granted 107,511 restricted shares to 18 incentive recipients at an adjusted price of 13.48 yuan per share[99] - In 2023, the company adjusted the grant price of restricted shares from 13.48 yuan to 8.85 yuan per share and increased the number of shares from 1,459,800 to 2,189,700[100] - In 2023, the company granted 889,717 restricted shares to 107 incentive recipients at an adjusted price of 8.85 yuan per share[100] - In 2024, the company canceled 1,190,348 restricted shares due to unmet performance targets and employee departures[100] - The company's 2023 annual revenue reached 1.194 billion yuan[100] - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserves into share capital for the first half of the year[99] - The company held its 2023 annual general meeting on May 20, 2024, with a 32.40% investor participation rate[97] - The company strictly adheres to the ISO14001-2015 environmental management system standard, effectively reducing "three wastes" emissions, lowering energy consumption, and saving resources, thereby promoting clean production and reducing organizational costs[102] - The company's actual controllers, Yan Jinyuan and Wang Shi, have committed to avoiding competition with the company and ensuring compliance with social insurance and housing provident fund systems[104] - The company's controlling shareholders and senior management have pledged not to reduce their holdings of company shares for six months starting from September 14, 2023, to support the company's stable development and protect investor interests[104] - The company has resolved two patent disputes with Shenzhen Mindray Bio-Medical Electronics Co., Ltd., with settlement amounts of 986,300 yuan and 826,800 yuan respectively, and will reverse the accrued estimated liabilities, which will not have a significant adverse impact on the company's current profits[105] - The company reached a settlement with Shenzhen Mindray Bio-Medical Electronics Co., Ltd. regarding patent ownership disputes, with Mindray agreeing to withdraw the lawsuits. The settlement will not have a significant adverse impact on the company's current profits[106] - The total amount of other pending litigation not meeting the disclosure threshold is 4.4986 million yuan, and these cases are still under review or acceptance without any judgment results[107] - The company's daily related-party transactions in 2024 align with actual production and operations, with no significant impact on daily operations or performance. The actual transaction amounts differ from the estimated amounts due to market demand and business development adjustments[109] - The total amount of related-party transactions for the reporting period is 164,000 yuan, accounting for 0.00% of similar transactions. The approved transaction limit is 12.1 million yuan, and the actual transactions did not exceed the approved limit[111] - The company did not engage in any asset or equity acquisition, sale, or joint external investment-related transactions during the reporting period[112][113] - There were no significant related-party transactions involving financial companies or financial business dealings with related parties during the reporting period[115][116] - The company did not have any trusteeship, contracting, or leasing situations during the reporting period[117] - The total approved guarantee amount for subsidiaries during the reporting period is 24,000 million yuan, with actual guarantee amount of 11,630.19 million yuan[120] - The total approved guarantee amount for subsidiaries at the end of the reporting period is 26,500 million yuan, with actual guarantee balance of 14,224.56 million yuan[120] - The actual guarantee balance (A4+B4+C4) accounts for 11.04% of the company's net assets[120] - The guarantee amount for Zhuhai Shenbao Medical Equipment Co., Ltd. (China Merchants Bank) is 3,000 million yuan, with actual guarantee amount of 1,742.57 million yuan[119] - The guarantee amount for Shenzhen Baoyuan Medical Equipment Co., Ltd. (China Merchants Bank) is 2,000 million yuan, with actual guarantee amount of 1,004.59 million yuan[119] - The guarantee amount for Suzhou Junkang Medical Technology Co., Ltd. (ICBC) is 12,000 million yuan, with actual guarantee amount of 7,577.4 million yuan[120] - The guarantee amount for Wuhan Keruidi Medical Supplies Co., Ltd. (China Merchants Bank) is 500 million yuan[119] - The guarantee amount for Zhuhai Baorui Medical Equipment Co., Ltd. (China Merchants Bank) is 2,000 million yuan, with actual guarantee amount of 2,000 million yuan[119] - The guarantee amount for Shenzhen Baoyuan Medical Equipment Co., Ltd. (Jiangsu Bank) is 1,000 million yuan, with actual guarantee amount of 400 million yuan[119] - The guarantee amount for Zhuhai Baorui Medical Equipment Co., Ltd. (Bank of Communications) is 500 million yuan, with actual guarantee amount of 500 million yuan[119] - The company reached a comprehensive settlement with Shenzhen Mindray Bio-Medical Electronics regarding patent infringement disputes, with Mindray withdrawing all related lawsuits[122] - The company initiated a
宝莱特:关于宝莱转债2024年付息的公告
2024-08-28 08:41
证券代码:300246 证券简称:宝莱特 公告编号:2024-066 本公司及董事会全体成员保证公告内容真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、"宝莱转债"(债券代码:123065)将于 2024 年 9 月 4 日支付第四年利息, 每 10 张"宝莱转债"(面值 1,000 元)利息为 18.00 元(含税)。 2、债权登记日:2024 年 9 月 3 日 3、除息日:2024 年 9 月 4 日 4、付息日:2024 年 9 月 4 日 5、本次付息期间及票面利率:计息期间为 2023 年 9 月 4 日至 2024 年 9 月 3 日,票面利率为 1.8%。 债券代码:123065 债券简称:宝莱转债 广东宝莱特医用科技股份有限公司 关于宝莱转债 2024 年付息的公告 6、"宝莱转债"本次付息的债权登记日为 2024 年 9 月 3 日,截止至 2024 年 9 月 3 日下午深圳证券交易所收市后,在中国证券登记结算有限责任公司深圳分公 司(以下简称"中国结算深圳分公司")登记在册的"宝莱转债"持有人享有本次派 发的利息,在 2024 年 9 月 3 日前(含当日) ...
宝莱特:第八届董事会第十七次会议决议公告
2024-08-16 10:07
证券代码:300246 证券简称:宝莱特 公告编号:2024-064 债券代码:123065 债券简称:宝莱转债 广东宝莱特医用科技股份有限公司 第八届董事会第十七次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司(以下简称"公司")于 2024 年 8 月 16 日以通讯表决及现场会议相结合的方式召开第八届董事会第十七次会议,会议通 知于 2024 年 8 月 13 日以电子邮件、电话及传真方式送达,公司董事会共有董事 九名,参与表决的董事共九名,符合《公司法》和《公司章程》的规定。 董事会 公司董事会综合考虑公司现阶段的基本情况、股价走势、市场环境等多重因 素,以及对公司长期稳健发展与内在价值的信心,为明确投资者预期,维护全体 投资者的利益,经全体董事认真讨论与审议,同意公司本次不向下修正"宝莱转 债"转股价格,同时自本次董事会审议通过后的次日起至未来 6 个月内(即 2024 年 8 月 17 日至 2025 年 2 月 16 日),如再次触发转股价格向下修正条款,亦不 提出向下修正方案。自 2025 年 2 月 ...
宝莱特:关于不向下修正宝莱转债转股价格的公告
2024-08-16 10:07
证券代码:300246 证券简称:宝莱特 公告编号:2024-065 债券代码:123065 债券简称:宝莱转债 广东宝莱特医用科技股份有限公司 关于不向下修正"宝莱转债"转股价格的公告 本公司及董事会全体成员保证公告内容真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、截至2024年8月16日,广东宝莱特医用科技股份有限公司(以下简称"公 司")股票已出现任意连续三十个交易日中至少有十五个交易日的收盘价低于 当期转股价格90%的情形。 2、公司于2024年8月16日召开第八届董事会第十七次会议,审议通过了《关 于不向下修正"宝莱转债"转股价格的议案》,公司董事会决定本次不向下修 正"宝莱转债"转股价格,且自本次董事会审议通过后的次日起至未来6个月内 (即2024年8月17日至2025年2月16日),如再次触发转股价格向下修正条款,亦 不提出向下修正方案。自2025年2月17日起算,若再次触发"宝莱转债"转股价 格的向下修正条款,届时公司将召开董事会会议审议是否行使"宝莱转债"转 股价格的向下修正权利。 公司于2024年8月16日召开了第八届董事会第十七次会议,审议通过了《关 于不向 ...
宝莱特:关于预计触发可转债转股价格向下修正条件的提示性公告
2024-08-09 09:58
证券代码:300246 证券简称:宝莱特 公告编号:2024-063 债券代码:123065 债券简称:宝莱转债 广东宝莱特医用科技股份有限公司 关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏。 特别提示: 1、证券代码:300246,证券简称:宝莱特 2、债券代码:123065,债券简称:宝莱转债 3、转股价格:24.02 元/股 4、转股期限:2021 年 3 月 11 日至 2026 年 9 月 3 日 一、可转换公司债券发行上市概况 1、可转债发行上市基本情况 经深圳证券交易所创业板上市委2020年第8次审议会议审核通过,并经中国 证监会证监许可[2020]1831号文同意注册。公司于2020年9月4日向不特定对象发 行了219万张可转换公司债券,每张面值为人民币100元,发行总额为人民币2.19 债券代码:123065 债券简称:宝莱转债 证券代码:300246 证券简称:宝莱特 公告编号:2024-063 亿元。本次发行的可转换公司债券向发行人在股权登记日收市后中国证券登记结 算有限责任公司深圳分公司登 ...
宝莱特:关于公司获得医疗器械注册证的公告
2024-08-05 09:54
证券代码:300246 证券简称:宝莱特 公告编号:2024-062 债券代码:123065 债券简称:宝莱转债 广东宝莱特医用科技股份有限公司 关于公司获得医疗器械注册证的公告 本公司及董事会全体成员保证公告内容真实、准确、完整,不存在虚假记载、 误导性陈述或重大遗漏。 一、基本情况 广东宝莱特医用科技股份有限公司(以下简称"公司")于近日获得国家药品 监督管理局(以下简称"国家药监局")颁发的《医疗器械注册证》。 上述产品上市后的实际销售情况取决于未来市场需求以及市场推广效果,公 司目前尚无法准确预测上述产品对公司未来营业收入的影响,敬请投资者给予关 注并注意投资风险。 1 证券代码:300246 证券简称:宝莱特 公告编号:2024-062 债券代码:123065 债券简称:宝莱转债 三、备查文件 1、国家药监局颁发的《中华人民共和国医疗器械注册证》 具体情况如下: | 序 号 | 产品名称 | 型号、规格 | 注册证编号 | 注册证 有效期 | | 注册分类 | 临床用途 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 血液透析 | ...
宝莱特:关于涉及诉讼事项达成和解的公告
2024-08-01 11:07
债券代码:123065 债券简称:宝莱转债 证券代码:300246 证券简称:宝莱特 公告编号:2024-061 2.上市公司所处当事人地位:被告。 3.涉案的金额:案件一(2023)闽 01 民初 547 号为 98.63 万元,案件二(2023) 闽 01 民初 548 号为 82.68 万元,案件三(2023)闽 01 民初 936 号 200.58 万元。 4.对上市公司损益产生的影响:由于本案已作和解处理,其对公司本期利润 具有一定影响,敬请广大投资者注意投资风险。本次诉讼进展不会对公司核心技 术和自主研发能力产生影响,不会影响公司正常的生产经营。 一、诉讼的基本情况 广东宝莱特医用科技股份有限公司 关于涉及诉讼事项达成和解的公告 本公司及董事会全体成员保证公告内容真实、准确、完整,不存在虚假记 载、误导性陈述或重大遗漏。 特别提示 1.案件所处的诉讼阶段:已达成和解。 截至本公告披露日前 12 个月内,除上述诉讼事项外,公司及控股子公司不 存在应披露而未披露的重大诉讼、仲裁事项。 四、对公司本期利润或期后利润的可能影响 广东宝莱特医用科技股份有限公司(以下简称"公司")与深圳迈瑞生物医 疗电子股份 ...